Module Leader: Paolo Ghia
14 September – 27 September 2026
This module presents core diagnostic technologies and analytical approaches used in the evaluation of chronic lymphocytic leukemia (CLL). It introduces key methods such as immunophenotyping, genetic assessment of TP53, immunoglobulin gene analysis, and the principles of measurable residual disease detection. Each lecture outlines the type of information these tools can provide and the general frameworks used to interpret their results within recognised diagnostic pathways. Together, the module offers a structured view of the technologies, analytical criteria, and interpretive concepts that contribute to the diagnostic characterisation of CLL.
Module Leader: Iñaki Martin
28 September – 11 October 2026
This module introduces key areas of basic research that contribute to current understanding of CLL. It provides an outline of major scientific themes including genomic complexity, epigenetic regulation, micro-environmental interactions, and signalling processes centred on the B-cell receptor. Each lecture presents core concepts and research observations that shape contemporary investigations into CLL biology and disease evolution.
Module Leader: Jennifer Brown
12 October – 25 October 2026
This module outlines key aspects of the clinical management of CLL across the disease course. It introduces principles for the initial assessment of patients who are managed with active surveillance, approaches to frontline treatment selection, and current understanding of resistance and management in the relapsed/refractory setting. The module also highlights emerging therapeutic strategies and evolving treatment concepts. Each lecture presents these themes in a descriptive manner, drawing on guideline frameworks, prognostic tools and contemporary trial data, without providing prescriptive recommendations.
Module Leader: John Byrd
26 October – 8 November 2026
This lecture introduces the principles and processes that underpin clinical trial activity and therapeutic development in CLL. It outlines how trial units are organised and governed, how emerging treatments are evaluated across clinical phases, and how scientific advances in CLL contribute to wider drug development efforts. The lectures describe foundational concepts including ethical and regulatory frameworks, interpretation of safety and efficacy data, and biological considerations relevant to target selection.
Module Leader: Alina Gerrie
9 November – 22 November
This module explores the role of patient engagement in strengthening and sustaining CLL services across diverse health systems. It highlights how individual patient perspectives, global advocacy networks, and structured patient and public involvement contribute to improved equity, access, research relevance and service design. The lectures draw on international initiatives, real-world examples and best-practice frameworks to illustrate how patient voices shape awareness, policy, research and resource development. Themes include lived experience, formation of patient organisations, co-production in research, and the specific barriers faced in low- and middle-income countries (LMICs) when accessing diagnostics and treatment. All content is presented descriptively, focusing on conceptual understanding rather than prescribing models of care.